Calypso Biotech

About:

Calypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases.

Website: http://www.calypsobiotech.com

Top Investors: Johnson & Johnson Innovation – JJDC, Inkef, Gilde Healthcare, M Ventures, Fountain Healthcare Partners

Description:

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

Total Funding Amount:

30.5M EUR

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Plan-les-ouates, Geneve, Switzerland

Founded Date:

2013-01-01

Contact Email:

info(AT)calypsobiotech.ch

Founders:

Alain Vicari, Yolande Chvatchko

Number of Employees:

11-50

Last Funding Date:

2021-09-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai